Manhattan Scientifics, Inc. Announces Chinese Patent Issued For The Early Cancer Detection Technology Platform

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Senior Scientific, LLC, a unit of Manhattan Scientifics (MHTX: OTCQB) and a developer of nanobiotechnology for the early detection and localization of cancer and other human diseases, today announced that the Company has recently been granted a patent by the Chinese Patent Office, Patent No. CN102695473 A, covering the “Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof.” This patent is an additional patent granted for its MRX™ cancer detection technology that has been granted and issued in by the U.S. Patent office under U.S. Patent No. US 9,095,270 B2.

“This patent significantly strengthens our IP portfolio for our core MRX technology. With our proprietary cancer detection technology now protected in both the U.S. and China, the two largest markets by population, we now have leverage to pursue a global commercialization and licensing strategy.”

Bob Proulx, COO and President of Senior Scientific said, “This patent significantly strengthens our IP portfolio for our core MRX technology. With our proprietary cancer detection technology now protected in both the U.S. and China, the two largest markets by population, we now have leverage to pursue a global commercialization and licensing strategy.”

About Manhattan Scientifics, Inc.

Manhattan Scientifics Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of transformative technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.

About Senior Scientific

Senior Scientific LLC (www.seniorscientific.com) is at the crossroads of biotechnology and nanotechnology. Our novel bioimaging and nanomagnetic detection systems have been developed specifically to detect cancer and other diseases earlier and with higher specificity than is currently possible. Senior Scientific is owned by Manhattan Scientifics, Inc., a publicly traded company dedicated to assisting scientific enterprises commercializes transformative new technologies

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company’s actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.